CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Radiesse (+) Injectable Implantdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02904057
NCT02904057N/ACompleted

Evaluation of the Merz Jawline Grading Scale (MJGS) Following Radiesse (+)® Correction of Subcutaneous Volume Loss and Contour Deficits of the Jawline - a Canadian Pilot Study

Merz North America, Inc.·interventional·Posted Sep 16, 2016·Updated Dec 10, 2020

In Brief

A clinical study evaluating Radiesse (+) Injectable Implant for Volume Loss of the Jawline. Completed, enrolled 29 participants.

Detailed Summary

This study will evaluate the sensitivity of the validated Merz Jawline Grading Scale (MJGS) to detect treatment effects following Radiesse (+) correction of subcutaneous volume loss and contour deficits of the jawline. Treatment effects detected on the MJGS will be correlated with assessments of aesthetic outcomes on the Global Aesthetic Improvement Scale (GAIS) and FACE-Q instrument

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 16, 2016
Enrollment StartJan 1, 2016
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 9.8 years ago

Interventions

Radiesse (+) Injectable Implantdevice

Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.